Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients

BACKGROUND: Tolvaptan, a vasopressin V2 receptor antagonist, has been shown to reduce the rates of growth in total kidney volume (TKV) and renal function loss in ADPKD patients, but also leads to polyuria because of its aquaretic effect. Prolonged polyuria can result in ureter dilatation with conseq...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Exp Nephrol
Huvudupphovsmän: Casteleijn, Niek F., Messchendorp, A. Lianne, Bae, Kyong T., Higashihara, Eiji, Kappert, Peter, Torres, Vicente, Meijer, Esther, Leliveld, Anna M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2016
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5497698/
https://ncbi.nlm.nih.gov/pubmed/27339446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10157-016-1297-1
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk